<ul>
	<li><strong>Elderly</strong>: No dosage adjustment is required.</li>
	<li><strong>Renal impairment</strong>: No dosage adjustment is required.</li>
	<li><strong>Hepatic impairment</strong>: No dosage adjustment is required (see section 5.2).</li>
	<li><strong>Pediatric population</strong>: The safety and efficacy of casirivimab and imdevimab in children &lt;12 years of age has not yet been established. No data are available.</li>
</ul>